ArticleRespiratory research2025
Development and evaluation of a novel nebulized dihydromyricetin formulation: enhanced pulmonary delivery and pharmacokinetic properties.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review of the Composition and Antimicrobial Roles of Extracts of Vine Tea (Ampelopsis grossedentata).Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Natural Products Targeting Airway Inflammation and Mucus Hypersecretion: Molecular Mechanisms and Therapeutic Potential for Respiratory Health.Nutrients · 2026Review
- Mechanistic Insights into Dihydromyricetin: Redox Modulation and Kinase-Mediated Control of Disease Pathogenesis.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRespiratory diseases are a major global health burden, and inhalation therapy offers efficient pulmonary targeting and therapeutic effectiveness. Dihydromyricetin (DMY), a natural flavonoid with anti-inflammatory and antiviral activities, shows limited clinical application due to poor solubility, instability, and low oral bioavailability caused by extensive first-pass metabolism.
methodsA nebulized inhalation formulation of DMY was developed to enhance solubility, stability, and bioavailability. Pharmacokinetics were evaluated in rats following inhalation and oral administration. Safety was assessed through pulmonary function testing and histological examination of major organs.
resultsInhalation delivery significantly improved DMY bioavailability in both lung and systemic circulation compared with oral dosing. No differences in pulmonary function or tissue morphology were observed between the inhalation and saline groups after short-term administration, suggesting preliminary safety, which warrants further investigation.
conclusionThe nebulized DMY formulation demonstrates enhanced bioavailability, effective pulmonary targeting, and favorable safety, providing a promising therapeutic strategy for respiratory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.